{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T02:07:08Z","timestamp":1773281228815,"version":"3.50.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2016,5,27]],"date-time":"2016-05-27T00:00:00Z","timestamp":1464307200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1007\/s10067-016-3318-6","type":"journal-article","created":{"date-parts":[[2016,5,27]],"date-time":"2016-05-27T06:14:15Z","timestamp":1464329655000},"page":"2765-2769","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Long-term efficacy and safety of interferon \u03b1-2a therapy in severe refractory ophthalmic Behcet\u2019s disease"],"prefix":"10.1007","volume":"35","author":[{"given":"Hadise","family":"Kavandi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alireza","family":"Khabbazi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sousan","family":"Kolahi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehrzad","family":"Hajialilo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farid Karkon","family":"Shayan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Oliaei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,5,27]]},"reference":[{"key":"3318_CR1","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/j.1479-8077.2007.00295.x","volume":"10","author":"AR Jamshidi","year":"2007","unstructured":"Jamshidi AR, Banihashemi AT, Gholami J et al (2007) Prevalence of Behcet\u2019s disease in Iran: a WHO-ILAR COPCORD stage I study. APLAR J Rheumatol 10:239\u2013243","journal-title":"APLAR J Rheumatol"},{"issue":"4","key":"3318_CR2","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/j.1756-185X.2010.01549.x","volume":"13","author":"F Davatchi","year":"2010","unstructured":"Davatchi F, Shahram F, Chams-Davatchi C et al (2010) Behcet\u2019s disease in Iran: analysis of 6500 cases. Int J Rheum Dis 13(4):367\u2013373","journal-title":"Int J Rheum Dis"},{"key":"3318_CR3","first-page":"145","volume-title":"Behcet\u2019s Disease","author":"K Nakae","year":"1993","unstructured":"Nakae K, Masaki F, Hashimoto T et al (1993) Recent epidemiological features of Behcet\u2019s Disease in Japan. In: Godeau P, Wechsler B (eds) Behcet\u2019s Disease. Elsevier Science Publishers B.V, Amsterdam, pp 145\u2013151"},{"key":"3318_CR4","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1479-8077.2006.00208.x","volume":"9","author":"Z Zhang","year":"2006","unstructured":"Zhang Z, Peng J, Hou X, Dong Y (2006) Clinical manifestations of Behcet\u2019s Disease in Chinese patients. APLAR J Rheumatol 9:244\u2013247","journal-title":"APLAR J Rheumatol"},{"issue":"5","key":"3318_CR5","doi-asserted-by":"crossref","first-page":"615","DOI":"10.3346\/jkms.2001.16.5.615","volume":"16","author":"D Bang","year":"2001","unstructured":"Bang D, Lee JH, Lee ES et al (2001) Epidemiologic and clinical survey of Behcet\u2019s Disease in Korea: the first multicenter study. J Korean Med Sci 16(5):615\u2013618","journal-title":"J Korean Med Sci"},{"issue":"1","key":"3318_CR6","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.1610-0387.2006.05841.x","volume":"4","author":"A Altenburg","year":"2006","unstructured":"Altenburg A, Papoutsis N, Orawa H, Martus P, Krause L, Zouboulis CC (2006) Epidemiology and clinical manifestations of Adamantiades-Behcet disease in Germany\u2014current pathogenetic concepts and therapeutic possibilities. J Dtsch Dermatol Ges 4(1):49\u201364","journal-title":"J Dtsch Dermatol Ges"},{"issue":"6","key":"3318_CR7","doi-asserted-by":"crossref","first-page":"423","DOI":"10.3349\/ymj.1997.38.6.423","volume":"38","author":"A Gurler","year":"1997","unstructured":"Gurler A, Boyvat A, Tursen U (1997) Clinical manifestations of Behcet\u2019s Disease: an analysis of 2147 patients. Yonsei Med J 38(6):423\u2013427","journal-title":"Yonsei Med J"},{"key":"3318_CR8","first-page":"48","volume-title":"Behcet\u2019s Disease","author":"KT Calamia","year":"2000","unstructured":"Calamia KT, Mazlumzadeh M, Balbanova M et al (2000) Clinical characteristics of United States patients with Behcet\u2019s Disease. In: Bang D, Lee E, Lee S (eds) Behcet\u2019s Disease. Design Mecca Publishing, Seoul, pp 48\u201351"},{"key":"3318_CR9","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1001\/archopht.1970.00990040453009","volume":"84","author":"JG Mamo","year":"1990","unstructured":"Mamo JG (1990) The rate of visual loss in Behcet\u2019s disease. Arch Ophthalmol 84:451\u2013452","journal-title":"Arch Ophthalmol"},{"key":"3318_CR10","first-page":"233","volume":"43","author":"F Davatchi","year":"2005","unstructured":"Davatchi F, Shahram F, Chams C, Chams H, Nadji A (2005) Behcet\u2019s Disease. Acta Med Iran 43:233\u2013242","journal-title":"Acta Med Iran"},{"key":"3318_CR11","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1136\/bjo.70.8.589","volume":"70","author":"D BenEzra","year":"1986","unstructured":"BenEzra D, Cohen E (1986) Treatment and visual prognosis in Behcet\u2019s disease. Br J Ophthalmol 70:589\u2013592","journal-title":"Br J Ophthalmol"},{"issue":"118(1)","key":"3318_CR12","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0002-9394(14)72840-5","volume":"15","author":"SM Whitcup","year":"1994","unstructured":"Whitcup SM, Salvo EC Jr, Nussenblatt RB (1994) Combined cyclosporine and corticosteroid therapy for sight-threatening uveitis in Behcet\u2019s disease. Am J Ophthalmol 15(118(1)):39\u201345","journal-title":"Am J Ophthalmol"},{"key":"3318_CR13","doi-asserted-by":"crossref","unstructured":"Khabbazi A, Noshad H, Shayan FK, Kavandi H, Hajialiloo M, Kolahi S (2014) Demographic and clinical features of Behcet\u2019s disease in Azerbaijan. Int J Rheum Dis(Oct 28)","DOI":"10.1111\/1756-185X.12512"},{"issue":"6","key":"3318_CR14","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1111\/j.1600-0420.1997.tb00638.x","volume":"75","author":"P Pivetti-Pezzi","year":"1997","unstructured":"Pivetti-Pezzi P, Accorinti M, Pirraglia MP, Priori R, Valesini G (1997) Interferon alpha for ocular Behcet\u2019s disease. Acta Ophthalmol Scand 75(6):720\u2013722","journal-title":"Acta Ophthalmol Scand"},{"key":"3318_CR15","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1046\/j.1365-2796.1998.00159.x","volume":"243","author":"S Georgiou","year":"1998","unstructured":"Georgiou S, Monastirli A, Pasmatzi E, Gartaganis S, Goerz G, Tsambaos D (1998) Efficacy and safety of systemic recombinant interferon-\u03b1 in Behcet\u2019s disease. J Intern Med 243:367\u2013372","journal-title":"J Intern Med"},{"issue":"5","key":"3318_CR16","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1136\/bjo.82.5.488","volume":"82","author":"I K\u00f6tter","year":"1998","unstructured":"K\u00f6tter I, Eckstein AK, St\u00fcbiger N, Zierhut M (1998) Treatment of ocular symptoms of Behcet\u2019s disease with interferon alpha 2a: a pilot study. Br J Ophthalmol 82(5):488\u2013494","journal-title":"Br J Ophthalmol"},{"key":"3318_CR17","first-page":"1437","volume":"84","author":"N Stubiger","year":"2000","unstructured":"Stubiger N, Kotter I, Zierhut M (2000) Complete regression of retinal neovascularisation after therapy with interferon in Behcet\u2019s disease [letter]. Br J Ophthalmol 84:1437\u20131438","journal-title":"Br J Ophthalmol"},{"key":"3318_CR18","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1076\/ocii.8.4.219.6460","volume":"8","author":"B Bodaghi","year":"2000","unstructured":"Bodaghi B, Gendron G, Wechsler B et al (2000) Efficacy of interferon alpha-2a in severe and refractory uveitis associated with Behcet\u2019s disease. Ocul Immunol Inflamm 8:293\u2013301","journal-title":"Ocul Immunol Inflamm"},{"issue":"12","key":"3318_CR19","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1055\/s-2001-19687","volume":"218","author":"N St\u00fcbiger","year":"2001","unstructured":"St\u00fcbiger N, K\u00f6tter I, Deuter C, Zierhut M (2001) Behcet\u2019s disease: uveitis-therapy with interferon alpha2a\u2014prospective clinical study in 33 patients. Klin Monbl Augenheilkd 218(12):768\u2013773","journal-title":"Klin Monbl Augenheilkd"},{"key":"3318_CR20","doi-asserted-by":"crossref","unstructured":"Alpsoy E, Durusoy C, Yilmaz E et al. Interferon alfa-2a in the treatment of Behcet\u2019s disease: a randomized placebo-controlled and double-blind study. Arch Dermatol 138:467\u201371","DOI":"10.1001\/archderm.138.4.467"},{"key":"3318_CR21","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1136\/ard.2007.080432","volume":"67","author":"G Hatemi","year":"2008","unstructured":"Hatemi G, Silman A, Bang D et al (2008) EULAR recommendations for the management of Behcet\u2019s disease. Ann Rheum Dis 67:1656\u20131662","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"3318_CR22","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1007\/s00417-006-0346-y","volume":"244","author":"I Tugal-Tutkun","year":"2006","unstructured":"Tugal-Tutkun I, G\u00fcney-Tefekli E, Urgancioglu M (2006) Results of interferon-alfa therapy in patients with Behcet\u2019s uveitis. Graefes Arch Clin Exp Ophthalmol 244(12):1692\u20131695","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"3318_CR23","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/jdv.12107","volume":"28","author":"International Team for the Revision of the International Criteria for Behcet\u2019s Disease (ITR-ICBD)","year":"2014","unstructured":"International Team for the Revision of the International Criteria for Behcet\u2019s Disease (ITR-ICBD) (2014) The International Criteria for Behcet\u2019s Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol 28:338\u2013347","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"3318_CR24","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s10067-013-2411-3","volume":"34","author":"F Davatchi","year":"2015","unstructured":"Davatchi F, Abdollahi BS, Chams-Davatchi C et al (2015) Validation of the revised International Criteria for Behcet\u2019s Disease (ICBD) in Iran. Clin Rheumatol 34(2):315\u2013320","journal-title":"Clin Rheumatol"},{"key":"3318_CR25","first-page":"134","volume":"32","author":"F Davatchi","year":"1991","unstructured":"Davatchi F, Akbarian M, Shahram F, Tebbi M, Chams C, Chams H (1991) Iran Behcet\u2019s disease dynamic activity measure. Abstracts of the XIIth European congress of rheumatology. Hungarian Rheumato 32:134, abstract FP10\u2013100","journal-title":"Hungarian Rheumato"},{"issue":"5","key":"3318_CR26","doi-asserted-by":"crossref","first-page":"536","DOI":"10.3109\/s10165-009-0191-z","volume":"19","author":"F Shahram","year":"2009","unstructured":"Shahram F, Khabbazi A, Nadji A, Ziaie N, Banihashemi AT, Davatchi F (2009) Comparison of existing disease activity indices in the follow-up of patients with Behcet\u2019s disease See comment in PubMed Commons below. Mod Rheumatol 19(5):536\u2013541","journal-title":"Mod Rheumatol"},{"key":"3318_CR27","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1136\/bjo.87.4.423","volume":"87","author":"I K\u00f6tter","year":"2003","unstructured":"K\u00f6tter I, Zierhut M, Eckstein AK et al (2003) Human recombinant interferon alfa-2a for the treatment of Behcet\u2019s disease with sight threatening posterior or panuveitis. Br J Ophthalmol 87:423\u2013431","journal-title":"Br J Ophthalmol"},{"issue":"5","key":"3318_CR28","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1136\/ard.62.5.492","volume":"62","author":"M Calg\u00fcneri","year":"2003","unstructured":"Calg\u00fcneri M, Ozt\u00fcrk MA, Ertenli I, Kiraz S, Apra\u015f S, Ozbalkan Z (2003) Effects of interferon \u03b1 treatment on the clinical course of refractory Behcet\u2019s disease: an open study. Ann Rheum Dis 62(5):492\u2013493","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"3318_CR29","first-page":"896","volume":"35","author":"L Krause","year":"2008","unstructured":"Krause L, Altenburg A, Pleyer U, K\u00f6hler AK, Zouboulis CC, Foerster MH (2008) Long term visual prognosis of patients with ocular Adamantiades-Behcet\u2019s disease treated with interferon-alpha-2a. J Rheumatol 35(5):896\u2013903","journal-title":"J Rheumatol"},{"key":"3318_CR30","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.ajo.2008.08.038","volume":"146","author":"J Gueudry","year":"2008","unstructured":"Gueudry J, Wechsler B, Terrada C et al (2008) Long-term efficacy and safety of low-dose interferon 2a therapy in severe uveitis associated with Behcet disease. Am J Ophthalmol 146:837\u2013844","journal-title":"Am J Ophthalmol"},{"issue":"7","key":"3318_CR31","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1016\/j.ophtha.2009.11.022","volume":"117","author":"G Sobaci","year":"2010","unstructured":"Sobaci G, Erdem U, Durukan AH et al (2010) Safety and effectiveness of interferon alpha-2a in treatment of patients with Behcet\u2019s uveitis refractory to conventional treatments. Ophthalmology 117(7):1430\u20131435","journal-title":"Ophthalmology"},{"issue":"9","key":"3318_CR32","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1002\/art.27581","volume":"62","author":"CM Deuter","year":"2010","unstructured":"Deuter CM, Zierhut M, M\u00f6hle A, Vonthein R, St\u00f6biger N, K\u00f6tter I (2010) Long-term remission after cessation of interferon-\u03b1 treatment in patients with severe uveitis due to Behcet\u2019s disease reported experience with IFN-\u03b1 in BD-uveitis is scarce. Arthritis Rheum 62(9):2796\u20132805","journal-title":"Arthritis Rheum"},{"issue":"3","key":"3318_CR33","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1001\/archophthalmol.2011.3","volume":"129","author":"S Onal","year":"2011","unstructured":"Onal S, Kazokoglu H, Koc A et al (2011) Long-term efficacy and safety of low-dose and dose-escalating interferon alfa-2a therapy in refractory Bechet uveitis. Arch Ophthalmol 129(3):288\u2013294","journal-title":"Arch Ophthalmol"},{"key":"3318_CR34","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.preteyeres.2007.09.002","volume":"27","author":"CM Deuter","year":"2008","unstructured":"Deuter CM, Kotter I, Wallace GR, Murray PI, Stubiger N, Zierhut M (2008) Behcet\u2019s disease: ocular effects and treatment. Prog Retin Eye Res 27:111\u2013136","journal-title":"Prog Retin Eye Res"},{"issue":"3","key":"3318_CR35","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s10384-006-0425-y","volume":"51","author":"M Accorinti","year":"2007","unstructured":"Accorinti M, Pirraglia MP, Paroli MP, Priori R, Conti F, Pivetti-Pezzi P (2007) Infliximab treatment for ocular and extraocular manifestations of Beh\u00e7et\u2019s disease. Jpn J Ophthalmol 51(3):191\u2013196","journal-title":"Jpn J Ophthalmol"},{"issue":"12","key":"3318_CR36","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1093\/rheumatology\/keu266","volume":"53","author":"V Calvo-R\u00edo","year":"2014","unstructured":"Calvo-R\u00edo V et al (2014) Anti-TNF-\u03b1 therapy in patients with refractory uveitis due to Beh\u00e7et\u2019s disease: a 1-year follow-up study of 124 patients. Rheumatology (Oxford) 53(12):2223\u20132231","journal-title":"Rheumatology (Oxford)"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-016-3318-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-016-3318-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-016-3318-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-016-3318-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,8]],"date-time":"2019-09-08T19:43:06Z","timestamp":1567971786000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-016-3318-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,27]]},"references-count":36,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["3318"],"URL":"https:\/\/doi.org\/10.1007\/s10067-016-3318-6","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,27]]}}}